Group 1: Strategic Development - The company will continue to deepen its "One Body, Two Wings, Three Depths" development strategy, focusing on orthopedic chronic diseases and integrating brand-oriented business models [2] - A "1+N" open R&D system will be accelerated to enhance innovation and optimize the "Six Forces Project" (market, product, innovation, brand, guarantee, and value) [3] Group 2: Financial Performance - In 2024, the company achieved an annual revenue of ¥973,864,163.02, a slight decrease of 0.71% year-on-year, with a net profit of ¥120,271,592.81, an increase of 8.91% [3] - For Q1 2025, the company reported a main revenue of ¥250,212,341.68, a year-on-year increase of 19.08%, and a net profit of ¥31,249,274.14, up by 0.33% [3] Group 3: Product Development and Market Position - The company has completed the construction of an intelligent production line for traditional Chinese medicine formula granules, achieving a breakthrough with 211 varieties registered by the end of 2024 [5] - The leading product, Panlong Qipian, ranked first in market share at 8.05% in the traditional Chinese medicine market for musculoskeletal diseases in urban and county-level public hospitals in H1 2024 [6] Group 4: Marketing and Sales Strategy - The company has established a comprehensive marketing network covering over 4,800 hospitals, 7,000 retail terminals, and 6,000 grassroots medical institutions across 30 provinces [7] - Emphasizing "Internet + Medicine," the company is enhancing digital marketing strategies and collaborating with major e-commerce platforms to improve brand competitiveness [4]